• If you are wondering whether Envista Holdings at US$24.29 offers good value or is already fully priced, the recent share performance gives you a useful starting point.
• The stock has pulled back 6.4% over the last 7 days and 4.0% over the last 30 days. It sits 12.0% higher year to date and 36.7% above where it was a year ago, while the 3 year and 5 year returns of 26.7% and 44.7% highlight a tougher longer term journey.
• Recent coverage has focused on Envista Holdings as a dental equipment and consumables business adjusting to shifting industry demand and competitive pressures. This helps frame how investors are currently thinking about its prospects. Additional commentary has also looked at how the stock is trading relative to its sector peers, giving context for the mixed short term and long term return profile.
• Envista Holdings currently has a valuation score of 3/6, which means it screens as undervalued on half of the checks used. The next sections will walk through the key valuation approaches before closing with a way to assess whether those numbers truly line up with the broader investment story.

Approach 1: Envista Holdings Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes projected future cash flows and discounts them back to today to estimate what the business might be worth right now. It focuses on the cash that could ultimately be available to shareholders, rather than just earnings.

For Envista Holdings, the model used is a 2 Stage Free Cash Flow to Equity approach. It starts with last twelve month free cash flow of about $224.9 million. Analysts provide explicit estimates for several years. Beyond that, Simply Wall St extrapolates the trend to build a full 10 year path, reaching projected free cash flow of about $418.4 million in 2035.

On this basis, the DCF model produces an estimated intrinsic value of about $38.64 per share. Compared with the recent share price of $24.29, this implies the stock trades at roughly a 37.1% discount to that intrinsic value. This points to an undervalued reading on this model.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Envista Holdings is undervalued by 37.1%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Envista Holdings Price vs Earnings

For profitable companies, the P/E ratio is a straightforward way to link what you pay for the stock to the earnings it generates. It lets you see how many dollars of share price you are paying for each dollar of current earnings.

What counts as a normal or fair P/E depends on what the market expects for future growth and how risky those earnings appear. Higher growth and lower perceived risk can justify a higher P/E, while slower growth or higher uncertainty usually go with a lower one.

Envista Holdings currently trades on a P/E of 58.48x. That sits above the Medical Equipment industry average of 24.14x and also above the peer average of 48.34x. Simply Wall St’s Fair Ratio for Envista Holdings is 29.03x, which is a proprietary estimate of the P/E that might be reasonable given factors such as earnings growth, profit margins, industry, market cap and company specific risks.

This Fair Ratio is more tailored than a simple peer or industry comparison because it blends those company specific drivers into a single benchmark. Comparing the current P/E of 58.48x with the Fair Ratio of 29.03x suggests Envista Holdings trades at a richer multiple than that tailored estimate.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Envista Holdings Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are introduced here as a simple way for you to attach a clear story to your numbers, linking your view of Envista Holdings future revenue, earnings and margins to a forecast and then to a fair value that can be set against today’s price.

On Simply Wall St’s Community page, Narratives are an accessible tool used by millions of investors, where you can see and compare different stories about Envista Holdings, such as a more optimistic view that supports a Fair Value around US$35.00 and a more cautious view closer to about US$20.01. You can then decide how your own expectations line up with that range.

Once you choose or build a Narrative that matches your view, the platform continuously updates that story when new information like earnings or news is added. This allows you to keep comparing its Fair Value with the live share price to help decide whether Envista Holdings currently looks closer to your buy, hold or sell zone based on your own assumptions rather than a single static metric such as the current P/E of 58.48x.

For Envista Holdings however we will make it really easy for you with previews of two leading Envista Holdings Narratives:

Start with the bullish view, which leans on margin expansion, disciplined cost control and buybacks to argue that the current share price leaves some room between today’s valuation and what analysts think the stock could be worth if their assumptions play out.

Fair value in this bullish narrative: about US$28.69 per share.

Implied undervaluation vs the last close of US$24.29: roughly 15%.

Revenue growth assumption: about 3.9% a year.

• Analysts building this case focus on steady global dental demand, especially in emerging markets, supported by Envista’s efforts in digital dentistry and higher R&D spend.
• They expect margin improvement from cost reductions, operating efficiency and higher contribution from products like Spark, while also factoring in ongoing headwinds from China procurement reforms, tariffs and FX.
• The fair value estimate reflects confidence that earnings and cash flow can grow enough for the stock to justify a higher multiple than today, helped by share buybacks and gradual improvement in profitability.

The bearish narrative starts from the same company, but applies stricter assumptions to what multiple investors might be willing to pay if growth, pricing and margins do not fully match the more optimistic view.

Fair value in this bearish narrative: about US$20.01 per share.

Implied overvaluation vs the last close of US$24.29: roughly 18%.

Revenue growth assumption: about 3.8% a year.

• This view flags structural pressure from tele-dentistry, preventive care and powerful dental service organizations that may keep pricing tight and put long run pressure on margins.
• It also highlights regulatory and cost risks, including volume based procurement in China and higher input costs, while still acknowledging that Envista is investing in digital products, emerging markets and cost reduction.
• The lower fair value mainly reflects the idea that even if revenues and earnings move higher, the stock could settle on a lower P/E than bullish analysts use, which would cap return potential from today’s price.

Taken together, these two Narratives give you a clear valuation range built from the same public data but very different expectations about pricing power, execution and what multiple the market might pay. Your task is to decide which set of assumptions feels closer to how you see Envista Holdings, then track how fresh results and news move the story over time.

Do you think there's more to the story for Envista Holdings? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.